Publication | Closed Access

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPathologyMulticenter Evolution StudyMultiple MyelomaOncologyRadiation OncologyPhase 1Cancer ResearchHealth Sciences